- Home
- Results news
- JFL Life Sciences
- Q2 FY27 results
JFL Life Sciences Q2 FY27 results: net profit up 159.1% to ₹5.13 crore, revenue ₹98.65 crore vs ₹29.91 crore
JFL Life Sciences Limited reported standalone revenue of ₹98.65 crore for Q2 FY27, up from ₹29.91 crore in Q2 FY26, with EBITDA of ₹6.65 crore and a net profit of ₹5.13 crore. Basic EPS rose to ₹1.28 from ₹0.60 in the year-ago quarter, while the EBITDA margin narrowed to 6.7% from 9.7%.
Key points
- Revenue was ₹98.65 crore in Q2 FY27, up ₹68.74 crore or 229.8% from ₹29.91 crore in Q2 FY26.
- EBITDA rose to ₹6.65 crore from ₹2.91 crore, an increase of ₹3.74 crore or 128.5%.
- The EBITDA margin fell 3.0 percentage points to 6.7% from 9.7%, and the PAT margin fell 1.4 percentage points to 5.2% from 6.6%.
- Net profit was ₹5.13 crore, up ₹3.15 crore or 159.1% from ₹1.98 crore, and basic EPS rose to ₹1.28 from ₹0.60.
- For H1 FY27, revenue was ₹109.75 crore against ₹41.49 crore in H1 FY26, and net profit was ₹5.34 crore against ₹2.73 crore.
How did JFL Life Sciences perform in Q2 FY27?
JFL Life Sciences reported standalone revenue of ₹98.65 crore in Q2 FY27, up ₹68.74 crore or 229.8% from ₹29.91 crore in Q2 FY26. EBITDA rose ₹3.74 crore or 128.5% to ₹6.65 crore, though the EBITDA margin fell 3.0 percentage points to 6.7% from 9.7%.
Profit before tax was ₹5.65 crore, up ₹3.43 crore or 154.5% from ₹2.22 crore, and net profit was ₹5.13 crore, up ₹3.15 crore or 159.1% from ₹1.98 crore. Basic EPS rose ₹0.68 to ₹1.28 from ₹0.60, while the PAT margin fell 1.4 percentage points to 5.2% from 6.6%.
Against Q1 FY27, revenue rose ₹87.55 crore to ₹98.65 crore from ₹11.10 crore, EBITDA rose ₹4.56 crore to ₹6.65 crore from ₹2.09 crore, and net profit rose ₹4.02 crore to ₹5.13 crore from ₹1.11 crore. Basic EPS increased by ₹0.94 to ₹1.28 from ₹0.34, and the EBITDA margin fell 12.2 percentage points to 6.7% from 18.9%.
| ₹ crore | Q2 FY27 | Q1 FY27 | Q2 FY26 | YoY | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 98.65 | 11.10 | 29.91 | +229.8% | +788.7% |
| Other income | 0 | 0.02 | 0.01 | ||
| Total expenses | 93 | 9.63 | 27.70 | +235.7% | +865.7% |
| EBITDA | 6.65 | 2.09 | 2.91 | +128.5% | +218.2% |
| EBITDA margin | 6.7% | 18.9% | 9.7% | −3.0 pp | −12.2 pp |
| Profit before tax | 5.65 | 1.49 | 2.22 | +154.5% | +279.2% |
| Tax | 1.42 | 0.38 | 0.24 | +491.7% | +273.7% |
| Net profit | 5.13 | 1.11 | 1.98 | +159.1% | +362.2% |
| EPS (₹) | 1.28 | 0.34 | 0.60 | +113.3% | +276.5% |
EBITDA here is revenue from operations less operating costs (total expenses excluding finance costs and depreciation): before other income and exceptional items. Growth is shown only when both figures are positive. Source: Company's results filing (XBRL).
What changed in JFL Life Sciences' costs and profit?
Total expenses rose ₹65.30 crore or 235.7% to ₹93 crore from ₹27.70 crore in Q2 FY26, outpacing the increase in revenue. The cost of materials was the largest line, up ₹61.41 crore or 230.4% to ₹88.06 crore from ₹26.65 crore.
Other expenses rose ₹2.07 crore or 985.7% to ₹2.28 crore from ₹0.21 crore, finance costs increased ₹0.24 crore or 54.5% to ₹0.68 crore from ₹0.44 crore, and depreciation rose ₹0.05 crore or 18.5% to ₹0.32 crore from ₹0.27 crore. Employee cost fell ₹0.06 crore or 23.1% to ₹0.20 crore from ₹0.26 crore.
Other income was nil against ₹0.01 crore in the year-ago quarter. Q2 FY26 included an exceptional gain of ₹0.01 crore, while there was no exceptional item in Q2 FY27. Tax expense rose ₹1.18 crore or 491.7% to ₹1.42 crore from ₹0.24 crore.
| ₹ crore | Q2 FY27 | Q2 FY26 | Change | Change % |
|---|---|---|---|---|
| Cost of materials | 88.06 | 26.65 | +61.41 | +230.4% |
| Employee cost | 0.20 | 0.26 | −0.06 | −23.1% |
| Finance costs | 0.68 | 0.44 | +0.24 | +54.5% |
| Depreciation | 0.32 | 0.27 | +0.05 | +18.5% |
| Other expenses | 2.28 | 0.21 | +2.07 | +985.7% |
| Total expenses | 93 | 27.70 | +65.30 | +235.7% |
| Other income | 0 | 0.01 | −0.01 | |
| Tax | 1.42 | 0.24 | +1.18 | +491.7% |
| Exceptional items | none | +0.01 (gain) |
Source: Company's results filing (XBRL).
How did the first half of FY27 go?
For H1 FY27, revenue was ₹109.75 crore against ₹41.49 crore in H1 FY26, an increase of ₹68.26 crore or 164.5%. Total income rose ₹68.26 crore or 164.4% to ₹109.77 crore from ₹41.51 crore.
Profit before tax for the first half was ₹7.14 crore, up ₹3.49 crore or 95.6% from ₹3.65 crore, and net profit was ₹5.34 crore, up ₹2.61 crore or 95.6% from ₹2.73 crore. EPS rose ₹0.79 to ₹1.62 from ₹0.83.
| ₹ crore | H1 FY27 | H1 FY26 | Change |
|---|---|---|---|
| Revenue from operations | 109.75 | 41.49 | +164.5% |
| Profit before tax | 7.14 | 3.65 | +95.6% |
| Net profit | 5.34 | 2.73 | +95.6% |
| EPS (₹) | 1.62 | 0.83 | +95.2% |
Source: Company's results filing (XBRL).
What do the balance sheet and cash flow show?
For H1 FY27, operating cash flow was ₹0.46 crore against ₹2.29 crore in H1 FY26. Investing cash flow was nil against an outflow of ₹0.66 crore, and financing cash flow was an outflow of ₹1.13 crore against ₹0.07 crore. Capital expenditure was nil against ₹0.10 crore.
| ₹ crore | As of 30 September 2026 | As of 31 March 2026 |
|---|---|---|
| Total assets | 149.32 | 106.25 |
| Total equity | 51.22 | 45.87 |
| Borrowings | 21.65 | 21.73 |
| Cash and equivalents | 0.19 | 0.86 |
| Inventories | 33.67 | 34.55 |
| Trade receivables | 90.37 | 53.26 |
Source: Company's results filing (XBRL).
| ₹ crore | H1 FY27 | H1 FY26 |
|---|---|---|
| Cash from operations | 0.46 | 2.29 |
| Cash from investing | 0 | −0.66 |
| Cash from financing | −1.13 | −0.07 |
| Capital expenditure | 0 | 0.10 |
Source: Company's results filing (XBRL).
How has JFL Life Sciences done over the last 7 quarters?
Revenue over the reported quarters moved from ₹11.73 crore in Q4 FY25 and ₹11.59 crore in Q1 FY26 to ₹29.91 crore in Q2 FY26 and ₹63.05 crore in Q4 FY26, before falling to ₹11.10 crore in Q1 FY27 and rising to ₹98.65 crore in Q2 FY27, the highest in the series.
Net profit was lowest at ₹0.08 crore in Q4 FY25 and reached ₹5.13 crore in Q2 FY27, the highest point in the series. The EBITDA margin peaked at 18.9% in Q1 FY27 and fell to 6.7% in Q2 FY27, against a low of 5.6% in Q4 FY26. Profit rose year on year in each of the last three quarters.
How did JFL Life Sciences shares react?
| After the filing | Stock |
|---|---|
| Reaction day | +4.9% |
Minutes are measured from the price when the filing appeared; days from the previous close. Source: MarketPing price-reaction measurement.
Quick answers
What was JFL Life Sciences' revenue in Q2 FY27?
Revenue from operations was ₹98.65 crore, up 229.8% from ₹29.91 crore in Q2 FY26 (standalone).
Did JFL Life Sciences make a profit in Q2 FY27?
Yes. Net profit was ₹5.13 crore, against a net profit of ₹1.98 crore in Q2 FY26.
What was JFL Life Sciences' EPS in Q2 FY27?
Basic earnings per share were ₹1.28, against ₹0.60 in Q2 FY26.
How did JFL Life Sciences shares react to the Q2 FY27 results?
On the reaction day the stock moved +4.9% from the previous close.
When did JFL Life Sciences announce its Q2 FY27 results?
On 2 November 2026, in a filing to the NSE.
Sources
- Outcome of Board Meeting (NSE, 2 November 2026) · PDF
How this was written: every figure in the tables and charts is calculated from the company’s filed results (XBRL) and MarketPing’s price measurements. The text is drafted with AI from those figures and the filings, and a checker removes any sentence carrying a number it cannot trace to them. How we write these.
This is information, not investment advice. MarketPing does not recommend buying or selling any security.